Skip to main content

Table 1 Patient demographics and Gene selection in Test set

From: A study of gene expression markers for predictive significance for bevacizumab benefit in patients with metastatic colon cancer: a translational research study of the Hellenic Cooperative Oncology Group (HeCOG)

Variable Test set   
Patients N 16   
Age Median 60.6   
  Range 24-71   
   N (%)   
Best response CR 3 (18.8%)   
  PR 9 (56.2%)   
  SD 2 (12.6%)   
  PD 2 (12.6%)   
Histological Grade 1-2 10 (62.6%)   
  3-4 5 (31.2%)   
Gender Female 8 (50%)   
  Male 8 (50%)   
Progressive disease within 8 months   6 (37.6%)   
Microarray analysis: Gene selection
Gene Name EntrezID Fold change in 8-month Progression-free cohort FDR
KLF12 Kruppel-like factor 12 11278 1.87 0.092
AGR2 Anterior gradient homolog 2 (Xenopus laevis) 10551 0.62 0.092
ALDH6A1 Aldehyde dehydrogenase 6 family, member A1 4329 0.63 0.092
MCM5 Minichromosome maintenance complex component 5 4174 0.48 0.157
TFF2 Trefoil factor 2 7032 0.45 0.002